Molecule Details
| InChIKey | XULSCZPZVQIMFM-IPZQJPLYSA-N |
|---|---|
| Canonical SMILES | CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 9.8 |
| Source | BindingDB;ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16261 |
|---|---|
| Drug Name | Odevixibat |
| CAS Number | 501692-44-0 |
| Groups | approved investigational |
| ATC Codes | A05AX05 |
| Description | Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC).[A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L348... |
Categories: Acids, Acyclic Alimentary Tract and Metabolism Benzazepines Bile Therapy Bile and Liver Therapy Fatty Acids Fatty Acids, Volatile Heterocyclic Compounds, Fused-Ring Ileal Bile Acid Transporter Inhibitor Ileal bile acid transport inhibitor Lipids P-glycoprotein substrates
Cross-references: BindingDB: 77040 CHEMBL4297588 ChemSpider: 8329135 Drugs Product Database (DPD): 23889 PharmGKB: PA166268805 RxCUI: 2563966 Wikipedia: Odevixibat